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Abstract 
Purpose 
Patients who undergo hematopoietic stem cell transplantation (HSCT) often experience physical 
and psychological problems, even long after treatment has been completed. This study was 
performed to evaluate the effects of a 12-week outpatient physical exercise program, 
incorporating aerobic and strength exercises, as compared to a usual care control condition on 
patients’ physical performance and psychosocial well-being. 
Methods: Patients who had completed HSCT up to 6 months earlier were randomly assigned to 
a supervised physical exercise program (n = 64) or a usual care control group  
(n = 67). Primary outcomes were quantified physical performance and self-reported physical 
functioning. Secondary outcomes were body composition measurement, quantified walking 
activity and patient-reported outcomes (physical activity, fatigue and health-related quality of 
life). Assessments were at baseline, immediately after program completion and at 3-month 
follow-up. 
Results: Significant intervention effects were observed at both post-treatment and follow-up on 
physical performance measures. No other outcomes yielded statistically significant group 
differences. 
Conclusion: Physical exercise should be considered in the management of HSCT recipients to 
improve physical performance after discharge from hospital. Further research is needed to 
determine how the program can be enhanced so that improved physical performance also 
translates into improved physical and psychosocial functioning in daily life. 
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Background  
 The number of hematopoietic stem cell transplantation (HSCT) survivors is increasing 
rapidly. Annually, more than 45,000 patients undergo HSCT worldwide [1]. HSCT is associated 
with considerable physical and psychological distress [2], which may have a significant impact on 
health-related quality of life (HRQOL), even years after completion of treatment [3]. HRQOL is a 
multidimensional construct, typically including physical, emotional and psychological health 
issues [4]. 
 Physical exercise (PE) has been demonstrated to improve physical and psychological 
health outcomes in breast [5], prostate [6], and head and neck cancer patients [7], and may be 
particularly helpful in maintaining or improving physical functioning [5,7]. In HSCT patients, PE 
has been proposed as a means of helping individuals recover from the de-conditioning and the 
associated loss of functional capacity and debilitating fatigue that can occur with prolonged lack 
of physical activity after the transplantation phase [8,9]. However, heterogenous effects of PE on 
psychological well-being (e.g., HRQOL) have been reported across studies [2]. 
 After discharge from hospital, positive effects of outpatient PE programs have been 
reported for both physical and psychological health outcomes [2,10]. Yet, few randomized 
clinical trials (RCT) have investigated the effectiveness and the therapeutic sustainability of an 
outpatient PE intervention on self-reported HRQOL [2]. 
 Most outpatient physical exercise (PE) interventions after HSCT have involved isolated 
aerobic exercise programs or strength training [2]. To add strength resistance training to the 
aerobic intervention may be important for increasing muscle strength and bone and muscle 
mass [2]. To date, few studies have combined both aerobic and strength exercise components in 
a single program [2]. 
 In general, the quality of previous studies has been less than optimal [2,11]. In particular, 
most have been single-group studies, or controlled clinical trials or RCT’s without appropriate 
randomization methods. Relevant methodological safeguards such as concealment of treatment 
allocation, use of intention-to-treat analyses and blinding have not been used consistently 
[2,12]. Several studies reported data from trials with small samples and a high percentage of loss 
to follow-up [2]. This underscores the need for larger RCTs of physical exercise interventions in 
HSCT recipients. 
 A challenge for researchers is that many HSCT patients are quite ill and unable to follow 
the standard guidelines for physical exercise as recommended by the American College of Sports 
medicine (ACSM) [11,13]. Thus, we designed a program in which participants performed a 
graded exercised endurance and strength program [13]. We hypothesized that a moderate 
supervised outpatient physical exercise program for HSCT recipients would be superior to usual 
care in enhancing physical performance, body composition, quantified walking activity, self- 
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reported physical activity, fatigue and self-reported HRQOL as assessed both immediately 
following the training program and at 3-month follow-up. 
 
Methods 
Study sample 
 The study sample included both male and female patients who were older than 18 years 
of age, who had at least a basic fluency in the German language, and were recruited from three 
weeks up to six months after autologous or allogeneic HSCT. All patients were recruited from 
the University Hospital Zurich and the Cantonal Hospital St. Gallen. Patients were excluded from 
the study in the case of graft versus host disease (except for grade I not requiring treatment), 
painful joints, instable osteolyses, chronic pain, lesions of the central or peripheral nervous 
system, uncontrolled cardiovascular disease, thyroid disease or diabetes. The ethical committees 
of the Cantons Zurich and St. Gallen approved the study. All patients provided written informed 
consent. The study was registered at clinicaltrials.gov (number NCT00402753). 
 
Design and procedures 
 The study was a prospective, two group randomized clinical trial (RCT) investigating the 
effect of an ambulatory PE program compared to an usual care control group (UCG), with 
assessments at baseline, after completion of the exercise program or an equivalent time point 
for the usual care condition, and at 3-month follow-up. All patients underwent physical 
performance tests and body composition measurements, and completed questionnaires at the 
same time of day. The patients wore an accelerometer during 7 days to assess daily walking 
activity. 
 
Random assignment and blinding 
 A minimization procedure [14] was used to achieve an optimal balance between groups 
for the factors age, sex and type of transplantation (autologous versus allogeneic HSCT) (Figure 
1). The patients were randomly allocated to PE or to the usual care group (UCG) after the 
baseline measurements were performed. The results of the randomization were stored in 
opaque envelopes. The allocation sequence and contents of the envelopes were concealed from 
the study personnel. Independent assessors who were blinded to group assignment carried out 
the assessments. The trainers of the PE intervention could not, by definition, be blinded. 
 
Physical exercise intervention and control group 
 The PE group received a 12-week, supervised physical exercise program, incorporating 
both endurance and resistive strength exercises. The program was performed twice weekly in a 
physiotherapy practice or fitness centre near the patient’s home. A physiotherapist or a physical 
  4 
 trainer was present during the PE program to provide patients with further instructions and to 
guarantee their safety. Ergometer-cycling was used as cardiovascular training. All patients 
started with a 10-minute warming-up on an ergometer-cycle or a walking tread-mill. The 
exercise was built up to maintain the aerobic performance for at least 20 minutes, at a pre-
defined individual heart rate (from 50-60%, increasing up to 70-80% of the estimated 
maximum heart rate) [2]. The maximum heart rate was determined by subtracting the patient’s 
age from 220 [13]. 
 Cardiovascular training was combined with progressive resistance training to address 
cancer-related decrease in muscle strength [15]. This training was done using dumbbells in order 
to also address physical coordination. The standard strength program included squats, step-ups 
and downs, barbell rotations, and upright rowing. The program could be extended with chest 
press, triceps extension, biceps curl, modified curl ups, and calf raises. Patients in the usual care 
group (UCG) received usual care, which did not involve any structured or supervised exercise, or 
any encouragement to do physical exercise. 
 
Study measures 
Sociodemographic and clinical data 
 Age, sex, education, marital status, and leisure time activity [16] were obtained via 
personal interview. Clinical variables, including diagnosis, stem cell donor type, and time interval 
between HSCT and study assessments were obtained from the patients’ medical records 
(table1). Adherence to the exercise program was assessed using an exercise diary kept by the 
patient. Patients were also requested to report non-protocol exercise and any adverse events 
associated with the exercise program. 
 
Primary outcome measures  
 A set of physical performance measures (knee extension and grip strength, walking 
speed, functional exercise capacity, table 2, and the physical function subscale of the EORTC 
QLQ-c30, table 3, were used as primary outcome measures). 
 Knee extension strength (maximum voluntary peak force in Nm) was assessed with a 
hand-held dynamometer (HHD, CompuFet, Hoggan Health Industries Inc, West Jordan, UT, USA) 
that has previously been shown to be reliable in patients with hematological malignancies (table 
2) [17]. 
 Grip strength (Kg) was assessed with a Jamar hydraulic dynamometer (Lafayette 
Instrument type J00105, Lafayette, IN, USA) which has good intra-tester reliability and 
concurrent validity table 2) [18]. 
 Walking speed was measured with a 50 foot (15.24 meter) walk test. The inter-tester 
agreement for this test is good (table 2) [19].  Functional exercise capacity was assessed 
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with the six minute walking test (6-MWT in meters), a widely used, reliable, sub-maximal 
exercise test that assesses the physiologic and functional status of patients (table 2) [19]. 
 Self-reported physical function was assessed with the German language version of the 
EORTC QLQ-C30 [4]. The QLQ-C30 is used widely in cancer clinical trials, and has been 
demonstrated to be both valid and reliable (table 3) [4]. 
 
Secondary outcomes 
 Body composition 
 Body composition, including weight, fat mass and fat free mass (table 4) was measured 
with dual x-ray absorbtiometry (DXA) using the Hologic QDR (Discovery 4500A, Montreux 
Switzerland) [20]. 
 
 Quantified walking activity 
 Walking activity, including daily average steps and peak activity, was quantified with the 
Step Activity Monitor 3 (SAM3, Cymatech Corporation, Seattle, WA, USA). Patients wore the 
SAM3 for 7 consecutive days, yielding a reliable and representative measure of movements on a 
day-to-day basis [21]. Due to the properties of the SAM3, none of the patients received 
feedback about the step watch measurements at any time during the study [22]. The SAM3 was 
programmed to start the day after assessments, were made in the patient’s environment. The 
quantified walking assessments were performed before and after the physical exercise program 
(table 5). 
 
 Physical activity, fatigue and HRQOL (Patient-reported outcomes) 
 Self-reported physical activity (total met-minutes / week) was assessed with the 
International Physical Activity Questionnaire (IPAQ) short-form, telephone-version (table 5). The 
IPAQ has adequate test re-test properties for monitoring group level physical activity in diverse 
settings [23]. 
 Fatigue was assessed with the German language version of the fatigue subscale of the 
Functional Assessment of Cancer Therapy /Anaemia Scale (FACT / An), which has excellent 
reliability (table 5) [24]. 
 HRQOL (tables 6 and 7) was assessed with the German language version of the EORTC 
QLQ-C30 (except for physical function, which was a primary outcome, table 3). The QLQ-C30 is 
used widely in cancer clinical trials, and has been demonstrated to be both valid and reliable [4]. 
 
Statistical analyses 
 The a-priori power analyses for a comparison between the randomized groups estimated 
a minimal requisite sample size of 64 patients per group in order to detect a moderate effect 
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size (d=0.50) with a power of 0.80 and a two tailed alpha of 0.05. Baseline comparisons were 
performed using an independent Student’s t-test, the 2 test [25]. All data were checked for 
allowable ranges, missing data and extreme values. In the final analyses, we did not perform any 
imputations. Multilevel linear models analyses (MLMA) [25], were used to compare differences 
between the PE group and the usual care group over time (baseline to follow-up). Square root 
transformation of the variables was performed, if the assumptions for MLMA could not be 
achieved [25]. For those outcomes that yielded overall statistical significance (i.e., group x time 
interactions), univariate analysis of (co-)variance was conducted to determine if the group 
differences were observed at 12 week and/or 24 week follow-up [25]. The magnitude of 
statistically significant group differences was expressed in terms of Cohens d-statistic [26]. An 
effect size of 0.20 was considered small, 0.50 moderate and 0.80 large [26]. Non-parametric 
tests (Wilcoxon) were performed for those outcomes that did not fulfil the assumptions for 
MLMA [25]. A p-value less than or equal to 0.05 was considered significant. In order to limit the 
possibility of type 1 errors due to multiple testing, p values were Sidak-adjusted. In practice, this 
meant that a p-value less than or equal to 0.01 was considered significant [27]. The p-values for 
the secondary outcomes were not adjusted. The statistical analysis was carried out on an 
intention-to-treat basis. For all statistical tests, SPSS 18.0 (SPPS Inc, Chicago, IL) was used. 
 
Results 
 Patients were enrolled from January, 2005 to November, 2008. We recruited 131 of 319 
screened (41.1%) and 131 of 230 (56.9%) eligible patients (Figure 1). One hundred twenty-two 
patients were recruited from the University Hospital Zurich and 9 from the Cantonal Hospital St. 
Gallen. Reasons for ineligibility (n=89) were medical condition (n = 56), insufficient 
understanding of the German language (n=17), participation in another physical exercise 
program (n=5), mental retardation (n=1) and imprisonment (n=1). Nine patients (n = 9) were 
very anxious about the imminent SCT. We appraised that participating in a study would increase 
the level of stress in these patients; therefore, they were excluded from the study. Reasons for 
declining to participate (n= 99) were lack of interest (n=60), travel distance (n=15), being too 
busy (n=13), and unwillingness to be randomized (n=3). Eight patients did not indicate why they 
chose not to participate. 
 One hundred thirty-one patients were randomly assigned to the PE (n=64) or CG (n=67) 
group. No significant differences were observed between groups for any sociodemographic or 
clinical characteristics at baseline (table 1). 
 
 We obtained complete baseline data for all patients, with the exception of walking 
activity (n=102). Follow-up data were available for 114 patients (87%) at program completion 
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and 105 patients (80%) at 3-month follow-up. There were no significant between-group 
differences at baseline for any of the objective or self-reported measures. 
 
Compliance with the PE program and loss to study follow-up 
 Reasons for drop-out of patients in the PE group and in the CG are given in the flow 
chart (figure 1). Seven patients (10.9%, 4 men and 3 women), discontinued the PE program and 
were lost to follow-up. The average participation in the PE program was 85% (range 21% to 
100%). This represents approximately 20.5 of 24 training sessions. Seven patients (10.9%) in 
the PE group reported > 4 hours of intensive physical exercise per week. Five patients (7.5%) in 
the CG reported undergoing supervised physical exercise, at their own initiative, at a level 
comparable to the program of the PE group (i.e., 3 hours of aerobic exercise per week). 
No adverse reactions or injuries were observed or reported as a result of either the assessments 
or the physical exercise intervention. 
 
Effects on primary outcomes 
 Table 2 displays the effects of the program on physical performance outcomes, and 
indicates the covariates used in the models. MLMA showed significant interactions between 
group and time for knee-strength (p = .008, 95%CI -22.83 to -3.52), walking speed (p = .000, 
95%CI .22 to .60) and functional exercise capacity (p = .011, 95%CI -32.4 to -4.4). No 
significant group x time interaction was observed for grip strength (p = .624, 95%CI -1.04 to 
.62). Planned contrast showed knee extension strength (p = .001), walking speed (p = .007) and 
functional exercise capacity (p = .007) improved after the PE intervention, compared to the UCG 
from baseline to 12 weeks. From baseline to 3 months follow-up, the PE group was superior to 
the UCG for knee strength (p = .000). The observed difference between groups for walking 
speed (p = .02) and functional exercise capacity (p = .02) was no longer statistically significant. 
The ES for the physical performance values varied between .56 and .69. Although decreasing 
slightly after 3 months (varying between .54 and .56), ES still indicated moderate treatment 
effects for knee extension strength and the 6-MWT (table 2). 
 There were no significant differences observed between the PE group and the UCG for 
the EORTC QLQ C-30 physical function subscale (table 3), between baseline and after 
completion of the program (p= .38), nor between baseline and follow-up (p = 0.03). 
 
Effects on secondary outcomes 
 No statistically significant group x time interactions were observed for body composition 
(p- values varying from .240 to .455, table 4), quantified walking activity (p- values varying from 
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 .095 to.108, table 5), self-reported physical activity (p = 0.763, table 5) or fatigue (p = .056, 
table 5). For MLMA, the p-values for the secondary HRQOL outcomes varied between .157 and 
.850 (table 6). The covariates used in the models are indicated in the footnotes of tables 4-6. 
The p-values for those outcomes that were analyzed with the Wilcoxon tests are reported in 
table 7. There was a statistically significant difference between groups for diarrhea (p = .01) and 
emotional functioning (p = .02) after completion of the program. 
 
Discussion 
 The PE program yielded significant benefit in terms of physical performance outcomes, 
both at immediate post-program and at 3-month follow-up assessment. These effects were of a 
moderate magnitude. Compared to baseline, the mean changes in knee strength were 40.6 Nm 
(after completion) and 42.7 Nm (at follow-up) for knee extension strength. All values exceeded 
the smallest detectable difference of 17.2 Nm for this strength measurement protocol [17]. 
 Compared to baseline, walking speed in the PE group improved by 9.5% after program 
completion and 11.9 % at follow-up; the 6MWT distance increased by 14% and 17.7%, 
respectively. These findings are consistent with an earlier report in which walking speed and the 
6-MWT improved by 12% and 14%, respectively, in a supervised exercise group of HSCT 
recipients [10]. 
 The predicted 6-MWT [28] and grip strength [29] values for allogeneic SCT patients (n = 
56) [30] prior to and after [31] (n = 44) HSCT, were compared to the baseline results of 
allogeneic SCT patients (n = 52) in our study. Prior to HSCT, the 6-MWT was reduced to less 
than 80% predicted in 32 patients (58%) and reduced to 60% predicted in 5 patients (9.6%) 
[30]. After HSCT [31], 17 patients (81%) performed less than 80% of the predicted 6-MWT 
value, compared to 12 patients (23%) in our trial, and 6 patients (29%) [31] performed less 
than 60% of the predicted value, compared to 1 patient (2%) in our trial. 
 Prior to HSCT [30], average grip strength was reduced to less than 80% predicted in 22 
patients (39%) and reduced to 60% predicted in 8 patients (15%). After HSCT [31], 33 patients 
(75%) performed less than 80% of the predicted grip strength value, compared to 15 patients 
(30%) in our trial, and 21 patients (47%) performed less than 60% of the predicted value [31], 
compared to 23 patients (45%) in our trial. 
 In this RCT, improvement in muscular strength, walking speed and walking distance 
resulting from the PE program did not translate into improvements in laboratory-based 
measures, real-world functioning measures or patient–reported outcomes, except for an 
improvement in diarrhea and emotional functioning. In contrast to our results, two earlier RCT’s 
of physical exercise following HSCT observed a significant benefit in terms of increased body-
weight [32,33] and two RCT’s reported significant effects for HRQOL, and for physical and 
emotional well-being [34,35]. Possible explanations for the discrepancy in outcomes observed 
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 between studies could be methodological (e.g., difference in sample-size) and/or substantive 
(e.g., differences in program frequency and intensity) in nature. 
 Knee extension, walking speed and functional exercise capacity yielded statistical 
significance after the training program. The observed improvement in functional exercise 
capacity in the PE group is particularly notable, given the fact that 20 minutes of aerobic exercise 
twice weekly represents a ‘minimal dose’ (i.e., low frequency) of physical exercise that falls 
below the guidelines of the American college of Sports Medicine. The results of this study 
suggest that a graded, moderate PE intervention improves physical performance outcomes in 
de-conditioned patients. We suspect that the effects of a PE intervention program on patient-
reported outcomes such as fatigue and HRQOL might be stronger if the frequency of the aerobic 
exercise training was increased from 2 to 3 times a week [35] and the duration was extended 
from 20 up to 45 minutes [36]. Interval training above the ventilatory threshold and above the 
V02peak in an advanced phase for fitter patients or in a follow-up PE intervention might further 
improve cardiovascular fitness [36]. 
 The positive results of the physical performance measures in our study are consistent 
with recent high quality studies [8 -10], investigating the effectiveness of physical exercise 
interventions in HSCT patients. Contrary to our results, significant effects have been reported for 
physical activity level (p = .0001), weight (p = .004), percentage body fat (p = .0006), BMI (p = 
.0002), quality of life (p = .03) and fatigue (p = .003) in studies among patients with breast and 
prostate cancer [37]. Additionally, quantified walking activity has been reported to be enhanced 
in (breast) cancer patients who participate in a combined physical activity and counselling 
program [38]. 
 In the current study, the PE program was individually-based. This approach was chosen 
to maximize the convenience of the program for the participants. However, group based 
physical training interventions have been shown to be effective in increasing cancer survivors’ 
HRQOL [39]. This probably reflects the psychosocial benefits that can accrue when group 
cohesion is created, providing social support and positive social comparisons. Additionally, 
cancer patients and survivors indicate that exercising in groups can increase one’s motivation to 
overcome their physical limitations [39]. 
 The current study included both patients who had undergone allogeneic and autologous 
HSCT. In autologous HSCT, the myeloablative treatment is less intense and hospitalization is 
considerably shorter than is typically for allogeneic HSCT cases [1]. It has been suggested that 
such treatment differences should be considered when comparing interventions and outcomes 
[8]. However, the baseline variables donor-type, diagnosis and time interval between HSCT and 
study assessments were examined as possible confounders, and were found to be non-
significant. 
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 Several possible limitations of the study should be noted. First, the study included a 
relatively large number of outcome measures. Therefore, to minimize the chance of making a 
type I error, p-value adjustments for correlated outcomes were considered. An objection to p-
value adjustments is that if the chance of making a type I error is reduced, the chance of making 
a type II error, which is no less important, may be increased [40]. Therefore, p-value adjustments 
were performed only among the primary outcomes. 
 Second, we did not perform a maximal graded exercise test administered by an exercise 
physiologist to determine the level of cardiovascular fitness. This is a more accurate measure of 
maximal oxygen consumption compared with the 6-minute walking test, which only provides an 
estimation of sub-maximal performance. Nevertheless, the 6 MWT-test showed an improvement 
immediately after program completion and at follow-up. 
Third, the percentage of drop-outs at follow-up was almost 20%. While this is not a trivial 
percentage, it is lower than the attrition reported in other similar studies, ranging from 25% to 
56% [2]. Third, although we were unable to document this due to limited access to data from 
study decliners, patients who were willing to participate in this study may have differed from 
those who declined participation in terms of such factors as age, education, earlier PE habits, 
fitness level, body mass index and resilience [15]. Future studies are needed to better understand 
why patients chose (not) to participate in PE programs, and how to improve recruitment rates 
[15]. 
 Potential biasing effects may have affected the quantitative walking activity 
measurements, as patients may have increased their physical activity level simply by virtue of the 
fact that they knew that they were being monitored. However, this type of reactive effect is 
likely to have affected both the PE and UC groups [22]. Another possible reason why we were 
unable to detect a significant difference between groups for walking is that the PE group was 
not advised to achieve a specific step count (i.e. 10’000 steps /day) [22,41,42]. 
 In conclusion, the results of our study indicate that physical performance, but not body 
composition, physical activity level in daily life, fatigue or HRQOL improves in HSCT recipients 
after a PE intervention. PE should be considered in the management of HSCT recipients after 
discharge from hospital. Additional efforts are needed to strengthen the effect of such 
programs, and to develop PE programs that attract a larger percentage of HSCT recipients. 
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Table 1. Baseline sociodemographic, clinical and behavioral profile of patients overall 
and by group assignment 
 All (n=131) PE (n=64) UCG (n=67)  
 n  % n  % n  % p-
value 
Age* 
Mean 
SD 
Range 
  
46.7 
12.8 
18-75 
   
46.7 
13.7 
18-75 
   
46.6 
12.0 
20-67 
 0.97 
Gender‡ 
Woman 
Man 
 
54 
77 
 
 
 
41.2 
58.8 
 
26 
38 
  
40.6 
59.4 
 
28 
39 
  
41.8 
58.2 
0.89 
Marital status‡ 
Single 
Married / Partner 
Divorced 
Widowed 
 
36 
79 
12 
4 
 
 
 
27.5 
60.3 
9.2 
3.1 
 
15 
40 
5 
4 
 
 
 
23.4 
62.5 
7.8 
6.2 
 
21 
39 
7 
0 
 
 
 
31.3 
58.2 
10.4 
0 
0.15 
Education‡ 
Secondary school 
Vocational  
Higher professional 
College / University 
 
18 
56 
21 
36 
  
13.7 
42.7 
16.0 
27.5 
 
8 
26 
12 
18 
  
12.5 
40.6 
18.8 
28.1 
 
10 
30 
9 
18 
  
14.9 
44.8 
13.4 
26.9 
0.83 
Diagnosis‡ 
Leukaemia 
Acute myeloid leukemia 
Chronic lymphocytic leukemia 
Acute lymphoblastic leukemia 
Lymphoma 
Hodgkin 
Non Hodgkin lymphoma 
Multiple myeloma 
Osteomyelofibrosis 
Amyloidosis 
Testicular cancer 
 
 
31 
14 
2 
 
14 
25 
37 
4 
1 
3 
 
 
 
 
 
23.7 
10.7 
1.5 
 
10.7 
19.1 
28.2 
3.1 
0.8 
2.3 
 
 
19 
5 
0 
 
5 
11 
17 
3 
1 
3 
  
 
29.7 
7.8 
0 
 
7.8 
17.2 
26.6 
4.7 
1.6 
4.7 
 
 
12 
9 
2 
 
9 
14 
20 
1 
0 
0 
  
 
17.9 
13.4 
3 
 
13.4 
20.9 
29.9 
1.5 
0 
0 
0.18 
Allogeneic/Autologous 
SCT-Type‡ 
 Allogeneic 
Autologous 
 
 
51 
80 
  
 
38.9 
61.1 
 
 
27 
37 
  
 
42.2 
57.8 
 
 
24 
43 
  
 
35.8 
64.2 
0.45 
Donor‡ 
Allogeneic 
Unrelated donor 
Related donor 
Autologous 
ASCT 1x 
ASCT 2x 
ASCT 3x 
 
 
30 
21 
 
57 
22 
1 
  
 
22.9 
16.0 
 
43.5 
16.8 
0.8 
 
 
17 
10 
 
28 
8 
1 
  
 
26.6 
15.6 
 
43.8 
12.5 
1.6 
 
 
13 
11 
 
29 
14 
0 
  
 
19.4 
16.4 
 
43.3 
20.9 
0 
0.53 
PE, Physical exercise, UCG; Usual care group, ASCT, Autologous stem cell transplantation. Statistical testing at baseline 
was done with an independent Student’s t-test* or Pearson X2 test‡. 
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Table 1. Baseline sociodemographic, clinical and behavioral profile of patients overall 
and by group assignment (continued) 
 All (n = 131) PE (N = 64) UCG (n=67  
 n  % n  % n  % p-
value 
Conditioning for allogeneic 
patients (N) ‡ 
Full intensity 
Reduced intensity 
ASCT 
 
 
33 
17 
80 
  
 
25.2 
13.0 
61.8 
 
 
15 
11 
38 
  
 
23.4 
18.2 
59.4 
 
 
18 
6 
43 
  
 
26.9 
9.0 
64.2 
0.37 
No. of patients in complete 
remission before HSCT* 
Yes 
No 
 
 
49 
82 
  
 
29 
71 
 
 
24 
40 
  
 
37.5 
62.5 
 
 
25 
42 
  
 
37.3 
62.7 
0.98 
TBI for allogeneic patients 
yes /no‡ 
 
23 
/108 
  
17.6 
82.4 
 
12 
/52 
  
18.8 
81.2 
 
11 
/56 
  
16.4 
83.6 
0.76 
Series chemotherapy before 
HSCT‡ 
One 
Two 
Three 
Four or more 
 
 
6 
27 
10 
88 
  
 
4.6 
20.6 
7.6 
67.2 
 
 
4 
13 
4 
43 
  
 
6.3 
20.3 
6.3 
67.2 
 
 
2 
14 
6 
45 
  
 
3.0 
20.9 
9.0 
67.2 
0.78 
Time interval (days) between 
HSCT and study assessments* 
Mean 
SD 
Range 
 
  
 
 
79 
35 
22- 
139 
   
 
 
81 
36 
27-
134 
   
 
 
78 
35 
22- 
139 
 0.68 
 
 
 
BMI* 
Mean 
SD 
Range 
  
23.4 
4.2 
14-38 
   
22.9 
4.3 
15-38 
   
23.9 
4.0 
14-
34 
 0.19 
Leisure time physical activity‡ 
Almost completely inactive 
Minimum 20 minutes 
walking/cycling/day 
 
44 
 
87 
  
33.6 
 
66.4 
 
25 
 
39 
  
39.1 
 
60.9 
 
19 
 
48 
  
28.4 
 
71.6 
0.19 
PE, Physical exercise, UCG; Usual care group, ASCT, Autologous stem cell transplantation. Statistical testing at baseline 
was done with an independent Student’s t-test* or Pearson X2 test‡. 
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Table 2. Effects on primary physical performance measures  
 Baseline At program 
completion 
At follow-up G x T 95%CI From 
baseline to 
program 
completion 
From 
baseline 
to follow-
up 
Outcome 
measure 
PE UCG PE UCG PE UCG p-value UB 
LB 
p 
 
d p 
 
 d 
Knee ext 
(Nm) 
Mean 
162.8 153.4 203.4 162.0 205.5 172.1 
SD 54.9 51.1 61.5 58.4 55.8 63.7 
.008 -22.83 
-3.52 
 
.001 .69 .000 .56 
Grip 
(Kg) 
Mean 
34.0 33.8 36.5 34.4 36.5 36.0 
SD 10.2 8.6 10.9 9.5 11.8 10.5 
.624 -1.04 
.62 
 
.30 .21 .61 .02 
Walking 
speed 
(Sec) 
Mean 
8.4 8.5 7.6 8.5 7.4 8.3 
SD 1.5 1.5 1.7 1.5 1.7 1.5 
 .000 .22 
.60 
.007 .56 .02 .56 
6-MWT 
(m) 
mean 
581.3 570.1 665.5 609.9 684.4 626.2 
SD 92.8 82.2 100.8 96.5 119.2 94.2 
.011 -32.4 
-4.4 
.007 .56 .02* .54 
For baseline data, after program completion and follow-up, raw unadjusted means are shown. The covariates used in 
the model for knee extension, grip strength, walking speed and 6-MWT were age, gender, type of stem cell 
transplantation-type and body mass index. Physical performance measures are primary outcomes (Sidak-adjusted p-
value = 0.01). All planned contrasts were performed with univariate analyses of co-variance, except for the 6-MWT* 
(from baseline to follow-up) that was performed with univariate analyses of variance. 
Abbreviations: PE; Physical exercise, UCG; Usual care group, G x T; Group x time intervention, UB; Upper boundary, LB; 
Lower boundary, p; p-value, d = effect size. 
Knee ext; Knee extension, Nm; Newton-meter, Kg; Kilogram, Walking speed; 50 foot walking at fastest speed test, 
Sec; seconds, 6-MWT; 6 minute walking test, m; meters. 
 
 
 
Table 3. Effects on HRQOL (primary outcome physical-functioning) 
 Baseline At program completion p-value At follow-up p-value 
Outcome PE UCG PE UCG  PE UCG  
Physical 
function 
        
Median 73.3 66.7 86.7 86.7 .38 93.3 86.7 .03 
Mean 71.9 67.8 83.7 80.4  87.4 82.4  
SD 18.0 17.0 14.2 14.0  14.1 15.7  
For baseline data, after program completion and follow-up, raw unadjusted means are shown, Sidak-adjusted p-value 
= 0.01.The analysis was performed with a non-parametric test (Wilcoxon). PE; Physical exercise, UCG; Usual care 
group. 
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Table 4. Effects on body composition 
 Baseline 
 
At program completion 
 
At Follow-up 
 
Group x 
time 
interaction 
95%CI 
Outcome 
measure 
PE UCG PE UCG PE UCG p-value 
F-value 
LB 
UB 
Weight       
Mean (Kg) 70.2 72.8 70.8 72.5 70.0 71.4 
SD 15.1 13.6 14.5 13.8 13.6 14.4 
 
.455 
.56 
 
-.55 
1.23 
Fat mass       
Mean 
(Kg) 
18.8 20.0 18.3 19.6 18.0 21.3 
SD 7.3 7.4 7.0 7.4 5.9 8.4 
 
.240 
1.38 
 
-0.42 
1.71 
Lean mass       
Mean 
(Kg) 
50.9 51.7 52.2 52.0 50.6 52.0 
SD 10.9 10.5 11.1 10.9 11.2 11.4 
 
.286 
.78 
 
-0.51 
0.68 
For baseline data, after program completion and follow-up, raw unadjusted means are shown. The covariates used in 
the analyses were time, gender and body mass index. PE; Physical exercise, UCG; Usual care group, LB; Lower bound, 
UB; Upper bound. 
 
 
 
Table 5. Effects on quantified walking activity, self-reported physical activity and 
fatigue 
 Baseline 
 
At program completion 
 
At follow-up 
 
Group 
x time 
interaction 
95%CI 
Outcome 
measure 
PE UCG PE UCG PE UCG p-value 
F-value 
LB 
UB 
Quantified walking activity (SAM) 
Average 
Steps* 
      
Mean 4924 4492 5099 5023 5102 5264 
SD 1790 1897 1493 2062 1828 2261 
.108 
2.61 
-.49 
4.93 
Peak 
activity 
      
Mean 42.3 41.3 43.9 42.6 42.0 44.0 
SD 7.0 7.7 5.9 9.0 7.6 8.8 
.095 
2.83 
-22 
2.75 
Self-reported physical activity (IPAQ) 
Total 
activity 
met-
min/wk* 
      
Mean 6735 6058 9738 8303 10343 9039 
SD 5817 5377 6699 9470 7408 7900 
.763 
.091 
-1.04 
3.45 
Fatigue (FACT-AN) 
FACT-AN       
Mean 35.9 32.8 43.6 40.0 42.3 41.9 
SD 10.3 9.2 8.4 7.5 9.1 7.3 
.056 
3.70 
-.04 
3.29 
For baseline data, after program completion and follow-up, raw unadjusted means are shown.  
*Outcomes were transformed; however, raw data were presented for use of interpretation.  
The covariates used in the analyses for quantified walking were gender and leisure time physical activity. The covariate 
used in the analyses for self-reported physical activity and self-reported fatigue was leisure time physical activity. PE; 
Physical exercise, UCG; Usual care group, LB; Lower bound, UB; Upper bound, SAM; Step activity monitor, IPAQ; 
International physical activity questionnaire; FACT/AN; Functional Assessment of Cancer Therapy /Anaemia Scale.  
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Table 6. Effects on secondary HRQOL outcomes  
(Results of mixed linear model analyses) 
 Baseline 
 
At program completion 
 
At follow-up 
 
Group x 
time 
interaction 
95%CI 
Outcome 
measure 
PE UCG PE UCG PE UCG p-value 
F-value 
LB 
UB 
Role  
function 
      
Mean 52.3 44.8 68.7 61.3 76.3 70.2 
SD 31.0 26.1 24.2 26.0 26.9 25.2 
.527 
.401 
-3.76 
7.34 
Cognitive 
function 
      
Mean 79.7 76.6 87.6 79.2 85.6 78.9 
SD 18.2 19.9 16.7 21.1 17.8 20.7 
.685 
.165 
-4.48 
2.95 
Social 
function 
      
Mean 56.8 57.0 71.3 72.9 78.5 75 
SD 29.9 24.6 28.6 24.9 26.3 25.5 
.850 
.036 
-5.83 
4.81 
GHS       
Mean 62.8 58.2 73.7 67.7 72.9 69.6 
SD 17.5 14.8 14.9 15.7 17.2 16.8 
.731 
.118 
-2.88 
4.09 
Fatigue       
Mean 47.6 54.6 31.6 38.3 30.1 32.1 
SD 25.5 22.9 22.1 20.0 24.9 19.1 
.157 
2.014 
-8.01 
1.30 
Pain*       
Mean 24.0 26.4 17.8 26.8 21.2 19.9 
SD 27.5 27.9 27.1 28.4 30.6 24.9 
.467 
.533 
 
-.26 
12 
Insomnia*       
Mean 30.2 34.3 23.0 31.5 26.3 25.0 
SD 30.1 31.2 27.4 30.8 31.9 30.9 
.592 
.289 
-.97 
.55 
For baseline data, after program completion and follow-up, raw unadjusted means are shown. *Outcomes were 
transformed; however, raw data were presented for use of interpretation.  
The covariates used in the analyses for HRQOL-models were age, gender, marital status, level of education and leisure 
time physical activity. LB; Lower bound, UB; Upper bound, PE; Physical exercise, UCG; Usual care group, GHS; General 
Health Score. 
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Table 7. Effects on secondary HRQOL outcomes 
(Results of non-parametric tests) 
 Baseline At program 
completion 
p-value At follow-up p-value 
Outcome PE UCG PE UCG  PE UCG  
Emotional 
function 
        
Median 75.0 66.7 83.3 75.0 .02 83.3 75.0 .07 
Mean 73.6 69.3 76.1 72.6  75.6 76.4  
SD 24.2 18.5 24.9 22.2  24.2 18.5  
Nausea 
Vomiting 
        
Median 0 0 0 0 .30 0 0 .46 
Mean 10.9 14.4 3.7 6.5  3.8 4.8  
SD 16.0 19.9 9.9 13.4  9.7 10.1  
Dyspnea         
Median 33.3 33.3 33.3 33.3 .39 0 33.3 .43 
Mean 34.4 43.8 21.8 29.2  19.2 25.6  
SD 33.1 29.7 24.6 23.0  24.1 25.2  
Appetite         
Median 0 33.3 0 33.3 .90 0 33.3 .48 
Mean 22.9 28.9 8.6 10.7  11.5 6.4  
SD 30.2 30.1 17.2 22.1  22.8 13.3  
Constipation         
Median 0 0 0 0 .09 0 0 .43 
Mean 4.7 7.0 4.6 7.7  7.1 5.8  
SD 14.4 17.0 17.0 16.8  15.2 15.8  
Diahrrea         
Median 0 0 0 0 .01 0 0 .17 
Mean 13.0 18.4 8.6 18.5  9.6 11.5  
SD 23.5 23.4 18.3 24.6  23.2 18.5  
Financial         
Median 0 0 0 0 .19 0 0 .09 
Mean 17.7 19.4 14.4 18.5  12.8 21.2  
SD 30.3 25.4 27.3 27.6  25.7 29.5  
For baseline data, after program completion and follow-up, raw unadjusted means are shown. Outcomes were 
analyzed with a non-parametric test (Wilcoxon). PE; Physical exercise, UCG; Usual care group. 
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319 patients after HSCT assessed for eligibility 
- Progressive disease n = 6 
- Co-morbidity other than cancer n = 1 
 
Assessments in 57 patients (89.1%) 
 
- Progressive disease n = 3 
- Busy with work n = 2 
- Lost interest in study n = 1 
- Assessments in 51 patients (79.7%) 
- Did not agree with allocation n = 2 
- Progressive disease n = 5 
- Co-morbidity other than cancer n = 2 
- Lost interest in study n = 1 
 
Assessments in 57 patients (85.1%) 
 
- Progressive disease n = 2 
- Co-morbidity other than cancer n = 1 
- Assessments in 54 patients (80.6%) 
Patients included in the intention-to-treat 
analyses n = 64 
Patients included in the intention-to-treat 
analyses n = 67 
Total excluded n = 188 (59%) 
Non-eligible n = 89 (28%) 
Declined n = 99 (31%) 
 
Baseline 
After  
program  
 
Follow-up 
Patients stratified by treatment type 
(allogeneic vs. autologous), by gender and 
by age (> or < 40 years) 
Randomized n= 131 (41%) 
Patients allocated to usual care control group 
n = 67 
Reported no regular exercise training n = 62 
(92.5%) 
Reported a minimum of 20 physical exercise 
sessions n = 5 (7.5%) 
Patients assigned to supervised 
physical exercise n = 64 
Attended < 66% of sessions n = 7 (10.9%) 
Attended > 66% n = 11 (17.2%) 
Attended > 80% n = 24 (37.5%) 
Attended 100%  n = 22 (34.4%) 
 
Figure 1. Consort diagram showing flow of the participants through the trial. 
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